Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, open label, single dose Safety and Pharmacokinetics study of SYM-1219 (Secnidazole) in Healthy Female Volunteers.

Trial Profile

Phase I, open label, single dose Safety and Pharmacokinetics study of SYM-1219 (Secnidazole) in Healthy Female Volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secnidazole (Primary)
  • Indications Bacterial vaginosis
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Symbiomix Therapeutics
  • Most Recent Events

    • 07 Nov 2016 According to a Symbiomix Therapeutics media release, data will be presented at the 2016 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition.
    • 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
    • 04 Mar 2015 According to a Symbiomix Therapeutics media release, results will be presented at the annual meeting of the American Society of Clinical Pharmacology and Therapeutics.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top